Quantification of haemagglutinin of influenza Tween-ether split vaccines by immunodiffusion

Johannsen, R.; Moser, Hans; Hinz, Joann M.; Friesen, Heinz-Jürgen; Gruschkau, H

doi:10.1016/0264-410x(85)90114-8

Cited by 12 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparably, in their investigations on influenza split vaccine products prepared by ether splitting and formaldehyde inactivation, Johannsen e.a. [ 24 ] found that the SRID underestimated the HA content by 25–50%, which was attributed to the aggregated state of the product, since an additional treatment to dissolve the aggregates (eg. octyl glucoside +Tween-ether or sonification in 1% Mulgofen in 0.9 M phosphate buffer pH 7.2) increased the HA content measured by SRID.…”

Section: Results and Specific Discussionmentioning

confidence: 99%

Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes

et al. 2016

View full text Add to dashboard Cite

The aim of this study was to evaluate the impact of different inactivation and splitting procedures on influenza vaccine product composition, stability and recovery to support transfer of process technology. Four split and two whole inactivated virus (WIV) influenza vaccine bulks were produced and compared with respect to release criteria, stability of the bulk and haemagglutinin recovery. One clarified harvest of influenza H3N2 A/Uruguay virus prepared on 25.000 fertilized eggs was divided equally over six downstream processes. The main unit operation for purification was sucrose gradient zonal ultracentrifugation. The inactivation of the virus was performed with either formaldehyde in phosphate buffer or with beta-propiolactone in citrate buffer. For splitting of the viral products in presence of Tween®, either Triton™ X-100 or di-ethyl-ether was used. Removal of ether was established by centrifugation and evaporation, whereas removal of Triton-X100 was performed by hydrophobic interaction chromatography. All products were sterile filtered and subjected to a 5 months real time stability study. In all processes, major product losses were measured after sterile filtration; with larger losses for split virus than for WIV. The beta-propiolactone inactivation on average resulted in higher recoveries compared to processes using formaldehyde inactivation. Especially ether split formaldehyde product showed low recovery and least stability over a period of five months.

show abstract

Section: Results and Specific Discussionmentioning

confidence: 99%

Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The protein content was determined by single radial immunodiffusion [9]. The meningococcal vaccine was Neisseria meningitidis group C-sized capsular oligosaccharide conjugated to a nontoxic mutant of diphtheria toxin CRM197 (MenC; Chiron) [ MenC -81 (29-220) -160 -NOTE.…”

Section: Vaccinesmentioning

confidence: 99%

Potency of a Genetically Detoxified Mucosal Adjuvant Derived from the Heat‐Labile Enterotoxin ofEscherichia coli(LTK63) Is Not Adversely Affected by the Presence of Preexisting Immunity to the Adjuvant

Ugozzoli¹,

Santos²,

Donnelly³

et al. 2001

J INFECT DIS

View full text Add to dashboard Cite

The objective of the current studies was to evaluate whether the potency of a genetically detoxified mucosal adjuvant, derived from heat-labile enterotoxin of Escherichia coli (LTK63), was adversely affected by preexisting immunity. Studies of mice and pigs have involved consecutive intranasal immunization with LTK63 and 2 different vaccines (influenza virus hemagglutinin and a protein-polysaccharide conjugate of Neisseria meningitidis group C). The antibody responses to the vaccines plus LTK63 in naive animals were compared with the responses achieved in animals that previously had been immunized with the alternate vaccine plus LTK63. The data showed that the responses of both animal models to intranasal immunization were not adversely affected by the presence of preexisting immunity to the LTK63 adjuvant.

show abstract

“…Purified monovalent A/Beijing8-9/93 (H3N2) influenza virus antigen was provided by Chiron Vaccines, Siena, Italy. Dosing was based on HA content as assayed by single radial immunodiffusion as described previously (15). LT-R72 was prepared as described previously (18).…”

mentioning

confidence: 99%

Intranasal Immunization of Mice with Influenza Vaccine in Combination with the Adjuvant LT-R72 Induces Potent Mucosal and Serum Immunity Which Is Stronger than That with Traditional Intramuscular Immunization

Barackman¹,

Ott²,

O’Hagan³

1999

Infect Immun

View full text Add to dashboard Cite

Immunization of mice by the intranasal route with influenza virus hemagglutinin in combination with the mutant Escherichia coli heat-labile enterotoxin R72 (LT-R72) induced significantly enhanced serum and mucosal antibodies, surpassing, in most cases, responses achieved by traditional intramuscular immunization using inactivated split influenza vaccine. Furthermore, intranasal immunization with LT-R72 induced a potent serum immunoglobulin G2a response, indicating that this adjuvant has Th1 character.

show abstract

Quantification of haemagglutinin of influenza Tween-ether split vaccines by immunodiffusion

Cited by 12 publications

References 6 publications

Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes

Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes

Potency of a Genetically Detoxified Mucosal Adjuvant Derived from the Heat‐Labile Enterotoxin ofEscherichia coli(LTK63) Is Not Adversely Affected by the Presence of Preexisting Immunity to the Adjuvant

Intranasal Immunization of Mice with Influenza Vaccine in Combination with the Adjuvant LT-R72 Induces Potent Mucosal and Serum Immunity Which Is Stronger than That with Traditional Intramuscular Immunization

Contact Info

Product

Resources

About